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The Reference Institute of Bioanalysis of the German
Society of Clinical Chemistry has performed the first
external assessment of molecular genetics methods
used in medical diagnosis. The following procedures
were tested: (I) DNA preparation from whole blood, (II)
PCR amplification using “standard” primers, and (III)
submarine agarose gel electrophoresis. Out of 50 par-
ticipants, 45 returned samples for evaluation.
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Introduction
During recent years, molecular genetic methods have
shown great potential in medical diagnostics. The
spectrum of techniques includes the detection of poly-
morphic sites and somatic and germ line mutations as
well as identification of tumour-specific transcripts and
microbial and viral genomes. Because of the multitude
of different applications it is still difficult to perform a
specific external quality control for every procedure.
Therefore, the Reference Institute of Bioanalysis of the
German Society of Clinical Chemistry in cooperation
with the Society’s working group on “Molecular Biol-
ogy Methods in Clinical Chemistry” attempted to ad-
dress the issue of quality assessment with a pilot study
to assess individual analytical steps in the complex
molecular diagnostic process using genomic DNA as
template. The PCR samples returned to the institute
were jointly evaluated in order to achieve better com-
parability of the results obtained in various laborato-
ries.
Participants and Control Materials
Participants in this external quality assessment trial for molec-
ular biology diagnostics came from institutes of human genet-
ics, medical genetics, and clinical chemistry as well as from
private medical laboratories. We received submissions from
Germany, Austria and Switzerland. Forty-five of the 50 trial
samples sent out were returned for joint evaluation.
Citrated blood from a female volunteer (DNA-1), DNA pre-
pared from leukocytes of a male volunteer (DNA-2), and
“standard” primers were sent out as control material and di-
agnostic reagents, respectively. The primer solution consisted
of a mixture of 4 oligonucleotides; K366-F: 5’-ATG GAA GTC
TAA AAG CCT GG-3’; K366-R: 5’-GAA GAG GTG TTT CCA CAG
AG-3’; SX9: 5’-GCA CCT TTC AAT TTT GTC GC-3’; and SX10; 
5’-AAG GCC TTT ATT AGC CAG AG-3’. Primers were received
from MWG-Biotech, Ebersberg, Germany, and used as sup-
plied. K366 primers amplify exon 4 of the human vitamin D-
binding protein gene located on chromosome 4 (1) and SX
primers are specific for the entire coding region of the human
SRY gene located on the Y chromosome (2). To choose the op-
timal PCR programme the participants received information
about the median Tm of all primers used, the optimal Mg2+-
concentration, and were told that the expected size of the PCR
products was in a range between 300 and 800 base pairs. The
PCR products utilizing DNA-1 as template were named P-D1
and using DNA-2 as template were named P-D2.
Results and Interpretation
Basic evaluation parameters and general comments
The basis for the evaluation of fragment lengths de-
scribed by the participants in the assessment trial was
the absolute fragment length in base pairs as deter-
mined by DNA sequence analysis. For the chromosome
4-specific fragment the length was 366 bp, and for the Y
chromosome-specific product, 779 bp, respectively.
Twenty µl of the returned PCR sample were mixed with 
5 µl of application buffer (20% Ficoll 400 in one fold con-
centrated Tris-Borate-EDTA [1xTBE] including brom-
phenol blue) for simultaneous electrophoretic separa-
tion. Seven µl of each mixture were analysed using 1%
agarose gels in 1xTBE buffer under identical conditions.
One or both of the samples returned by participants no.
17, 18, 22, 23, 25, 29, and 39 contained either too little or
no material for the joint analysis. After electrophoresis,
the ethidium bromide stained gels were digitalised un-
ter UV light using a videosystem (MWG-Biotech). A
semi-quantitative examination of the products was car-
ried out by densitometry with RFLP Scan V2.1 (Scanalyt-
ics, Vienna, USA). Amplitudes of absorption were re-
lated to the 500 bp band of the DNA length standard (1 kb
ladder, Gibco/BRL) applied to all gels in order to com-
pensate for differences in staining and/or digitalisation.
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Various methods for DNA preparation, different ther-
mophilic polymerases, PCR cyclers and programmes
as well as agarose gel electrophoretic procedures were
used as analytical systems. The PCR products of all par-
ticipants in the trial are presented in Figure 1. The PCR
with these “standard” primers permits a sex-specific
diagnosis of DNA. In the case of female DNA, a product
with a length of 366 bp (P-D1) is anticipated, and two
products with a length of 366 bp and 779 bp (P-D2) are
expected using male DNA.
The implementation of a polymerase chain reaction
not established in a laboratory is certainly difficult.
However, since most of the participants obtained
largely comparable results, the divergences observed
in some cases might allow some conclusions regard-
ing the quality of reagents and analytical systems used.
The bands obtained by most participants in the P-D2 re-
action with a length of about 500 bp are highly variable
in intensity and are seen as strong secondary bands.
Analysis of the individual primers using mass spec-
trometry showed disruptions in the synthesis of primer
SX9, which is one of the primers specific for the Y chro-
mosomal 779 bp product (data not shown). This might
cause mispriming during PCR using male DNA as tem-
plate, but other mechanisms such as non-optimised
Mg2+ concentration in the buffer system used could
also be responsible for this observation. Further strong
or weak secondary bands seen by only some partici-
pants are most likely attributable to the analytical mod-
ules and/or reagents used.
DNA preparation
The comparison of the densitometric results of the 366
bp product from the P-D1 and P-D2 reactions (Fig. 2) al-
lows certain conclusions regarding the quality of pre-
pared DNA in comparison to the control DNA provided.
Twenty-seven samples were evaluated. The criterion
for assessment was the clear evidence of the 366 bp
bands in both reactions and the 779 bp fragment in re-
action P-D2, their easy differentiation from secondary
bands and the fact that sufficient material was returned
for the joint evaluation. According to these criteria four
participants achieved a high quality (quotient > 1.0),
nine attained moderate qualities (between 0.7 and 1.0),
and the DNA preparation from 14 participants showed
a considerably lower quality (< 0.55). In 15 of the partic-
ipants included in this evaluation, the DNA was pre-
pared from whole blood using commercial kits and in
12 the DNA was extracted according to methods pub-
lished in the literature (3–9) or developed in their own
laboratories. The mean quality of DNA prepared by us-
ing commercial kits was considerably lower compared
to that of all other methods (Fig. 3). A possible reason
could be that commercial kits are not optimised to ex-
tract high quality DNA suitable for PCR amplification
from citrated blood used in this trial. The best quality of
DNA was achieved by preparing the DNA according to
the method described by Miller et al. (3). That was also
the procedure used to prepare the distributed control
DNA.
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Fig. 1 Joint electrophoretic evaluation of PCR products re-
turned by 45 participants in the programme. The gels con-
sisted of 1% agarose (UltraPURE, Gibco/BRL) in 1 x TBE.
P-D1: female DNA prepared from whole blood by the partici-
pants; P-D2: male control DNA prepared according to ref. 3
were used for PCR amplification. Fragment size in base pairs
is indicated at the right margin.
Fig. 2 Ratio of densitometric results of the 366 bp product
from P-D1 and P-D2 reactions. Insert shows the statistical
analysis of results from 27 participating laboratories.
Fig. 3 Densitometric P-D1/P-D2 ratio of the 366 bp products
according to the DNA preparation procedures.
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PCR System
The densitometric ratio of the 366 bp and 779 bp prod-
ucts of the P-D2 preparation allows some conclusions
regarding the PCR system used (Fig. 4). Balanced amp-
lification conditions should produce equal amplifica-
tion of these two products. Since all participants used
the DNA control material for this part of the trial, the
amplification reactions comprise the thermophilic
polymerase, buffer conditions as well as the instru-
ments used. The returns of 33 participants were evalu-
ated. Inclusion criteria for this evaluation were that
both bands were clearly visible without interferences
from secondary bands. The mean ratio of the O.D. of
the 779 bp fragment to the O.D. of the 366 bp fragment
in all samples was 0.43 (SD 0.29). Almost all reactions
performed by the participants led to a stronger amplifi-
cation of the 366 bp product. Thus, for future quality as-
sessment trials, it might be necessary to give addi-
tional information on the sequences of primers and the
degree of multiplexing of the PCR.
Fragment length determination
The fragment lengths stated by the individual partici-
pants in the trial are presented in Figure 5 (366 bp frag-
ment) and Figure 6 (779 bp fragment). Forty-two of the
45 returned results could be included in this analysis.
Three participants either did not report a result of the
results were devidently based on an error in interpreta-
tion of length in gel evaluation. The mean value (XM)
and standard deviation (SD) of all length determina-
tions are illustrated in each figure. The fragment
lengths defined by the majority of the participants were
too high. The absolute specifications of the 366 bp frag-
ments (SD ± 23.4 bp) were generally more accurate
than in the case of the 779 bp fragment (SD ± 56.8 bp),
although the percentage of errors was very similar
(6.4% and 7.3%, respectively).
Conclusions
In the first external quality assessment trial for molecu-
lar genetics procedures performed by the Reference In-
stitute of Bioanalysis of the German Society of Clinical
Chemistry, most of the participants obtained compar-
able results. The discrepancies that are observed in
some cases allow some conclusions regarding the
quality of reagents and/or analytical systems used.
This is a pilot study, which is an important step for the
future development of better external quality assess-
ment procedures in this field.
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Fig. 4 Ratio of densitometric results of the 366 bp and 779 bp
products from P-D2 reactions. Insert shows the analysis of re-
sults from 33 participating laboratories.
Fig. 5 Distribution of the fragment length determination of
the 366 bp product as determined by participants. Insert
shows the analysis of results from 42 participating laborato-
ries.
Fig. 6 Distribution of the fragment length determination of
the 779 bp product as determined by participants. Insert
shows the analysis of results from 42 participating laborato-
ries.
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